Category Archives: Category

ImmunoPreCept at the BUA Grand Challenges Conference 2026

A strong and inspiring start to the BUA Grand Challenges Conference 2026 in Berlin, bringing together researchers, practitioners, and partners to tackle some of the most pressing challenges of our time. ImmunoPreCept was actively represented, with our spokesperson Britta Siegmund contributing to the opening-day panel “Designing Grand Challenges Research: Principles, Perspectives, Partnerships.”

The discussion highlighted the importance of bold, interdisciplinary collaboration and the need to connect cutting-edge research with societal impact—core principles that are central to ImmunoPreCept’s mission. The conference once again demonstrated Berlin’s strength as a hub for collaborative, forward-looking science.

Learn from the three spokespersons how ImmunoPreCept is revolutionizing immune system therapies with innovative approaches that could transform the future of medicine. 

Prof. Britta Siegmund discusses how the ImmunoPreCept cluster aims to transform medicine by studying early disease stages, using single-cell technologies and AI for prevention, and engaging society to promote precision health.

Zusammenfassung:

Dies ist ein ausführliches Interview mit Prof. Britta Siegmund, einer der Sprecherinnen des Exzellenzclusters „ImmunoPreCept“,  in dem sie erläutert, wie das neue Konsortium die Medizin grundlegend verändern will. Das Interview behandelt die Forschungsschwerpunkte des Clusters, das sich auf die Vorstufen von Erkrankungen konzentriert, die molekularen und zellulären Mechanismen zur Erhaltung von Gesundheit, sowie die Anwendung modernster Einzelzelltechnologien und Künstlicher Intelligenz zur Früherkennung und Verhinderung chronisch-entzündlicher Krankheiten und Krebs. Ferner geht es um das gesellschaftliche Engagement, um ein neues Bewusstsein für Präzisionsprävention zu schaffen, und um konkrete Ziele, die in den kommenden sieben Jahren erreicht werden sollen.

Summary:

This is an in-depth interview with Prof. Britta Siegmund, one of the spokespersons for the ImmunoPreCept Cluster of Excellence, in which she explains how the new consortium aims to fundamentally change medicine. The interview covers the cluster’s main areas of research, which focus on the early stages of disease, the molecular and cellular mechanisms for maintaining health, and the application of state-of-the-art single-cell technologies and artificial intelligence for the early detection and prevention of chronic inflammatory diseases and cancer. It also addresses the cluster’s social commitment to creating a new awareness of precision prevention and the specific goals to be achieved over the next seven years.

ImmunoPreCept and NeuroCure are advancing Berlin medical research—preventing immune-driven diseases and translating neurological discoveries into patient care.

Discover how two important Clusters of Excellence at Charité, NeuroCure and ImmunoPreCept, are advancing medical research in Berlin. This release highlights ImmunoPreCept’s desire to comprehend how health tips into disease in order to identify and prevent immune-driven ailments before their symptoms manifest. Concurrently, NeuroCure, a trailblazer in brain science, continues its creative endeavors to swiftly translate developments in neurology and psychiatry into medications that benefit patients. Examine how these interdisciplinary projects, motivated by collaboration and cutting-edge research, could revolutionize medical treatment and prevention.